BPC-157 vs TB-500

BPC-157 has been studied in several animal injury models and a few small human reports. Research on the defined acetylated TB-500 fragment is largely analytical or laboratory work. A small 2026 rat study tested BPC-157 alongside a TB-500-labeled preparation, but the paper did not fully identify that preparation or establish a clear difference between the two compounds.

Research reviewed 2026-10-14. Educational information only.

The materials determine which papers apply

BPC-157 and TB-500 appear together in discussions of tissue repair because their literature touches cell movement, injury and the organization of healing tissue. They have different chemical identities and development histories. BPC-157 is a synthetic 15-residue peptide with the sequence GEPPPGKPADDAGLV. FDA’s 2026 BPC-157 assessment distinguishes the free base from its acetate form, a distinction relevant to identifying the preparation in a report.

For TB-500, the most useful starting point is a defined sequence: Ac-LKKTETQ, an N-terminally acetylated seven-residue fragment corresponding to positions 17–23 of thymosin beta-4. Esposito and colleagues identified that fragment in a TB-500-labeled product in 2012. FDA’s 2026 assessment evaluates this fragment and its acetate form. Full-length thymosin beta-4 contains 43 residues; unacetylated LKKTETQ is another preparation. A result obtained with one of these peptides cannot establish what another one will do.

This identity work becomes especially consequential in the direct tendon comparison. Its authors used a preparation labeled TB-500 and supplied a product code, but the paper provides no sequence or independent structural characterization. Without the sequence, we cannot tell whether the product was the defined acetylated fragment, so its tendon result cannot be confidently assigned to that fragment.

The main differences

From cell behavior to repaired tendon strength

What the earlier experiments measured

Tendon repair requires cells to reach the injury, remain viable and organize a collagen-rich matrix that can carry force. Chang and colleagues (2011) studied BPC-157 in rat Achilles-tendon explants and isolated tendon fibroblasts. They observed greater outgrowth, migration, spreading and survival under oxidative stress, accompanied by changes in actin and attachment-associated FAK/paxillin signaling. Their assays found no direct increase in fibroblast proliferation. This helps specify the observed response: the experiments measured several components of cell movement and survival, with a different result for direct proliferation.

Earlier whole-animal work by Staresinic and colleagues (2003) followed rats after complete, unrepaired Achilles-tendon transection. Compared with saline, intraperitoneal BPC-157 improved mechanical, walking-related and tissue-structure measurements over assessments through day 14. That model began with a gap between the cut tendon ends. It differs from a tendon immediately repaired by a surgeon and tested later, which matters when interpreting the newer result.

Defined acetylated TB-500 has a smaller experimental record. Rahaman and colleagues (2024) examined the fragment and its metabolites in laboratory systems, rat urine and a fibroblast scratch assay. The investigators scratched a gap into a layer of cultured fibroblasts and measured how much the gap closed. Cells exposed to the breakdown product Ac-LKKTE closed the gap more than control cells, with a statistically significant difference. The comparison using the original TB-500 fragment did not establish the same effect. These results distinguish the fragment from one of its breakdown products in this cell assay.

The adjacent thymosin literature helps explain the interest but introduces additional materials. Philp and colleagues (2003) studied full-length thymosin beta-4 in diabetic and aged mice with skin wounds, and an unacetylated LKKTETQ fragment in aged animals. Full-length thymosin beta-4 increased wound contraction and collagen deposition in the diabetic and aged mice; the unacetylated fragment also promoted repair in aged mice. Skin closure in these animals helps explain the interest in tendon repair, but the tested peptide, tissue and injury differ from acetylated TB-500 in a surgically repaired Achilles tendon.

The direct 2026 comparison

Biçer and colleagues (2026) cut and immediately repaired the Achilles tendons of 32 young male Sprague-Dawley rats. They randomly assigned eight rats each to BPC-157, the product identified as TB-500 in the study, both peptides or neither peptide. The last group received the injection liquid without either peptide; the authors call this liquid the vehicle but do not specify its composition. The rats received daily injections into the abdominal cavity through day 30. At that point, four tendons from each group were pulled until they broke, while the other four were examined for tissue changes.

The repaired tendons from rats given BPC-157 or TB-500 withstood more pulling force before breaking than those from rats given neither peptide. This force is the maximum load to failure. Only the TB-500 comparison with the group given neither peptide met the threshold for statistical significance after adjustment for multiple comparisons (P=0.0406); the corresponding BPC-157 comparison gave P=0.389. The study did not establish a difference in this measurement between the two peptides or an added benefit from combining them. Selected tissue scores also showed better organization in the TB-500 group than in the group given neither peptide.

A statistically significant result for one peptide against the group given neither peptide, alongside an uncertain result for the other, does not establish that the first peptide works better. That requires a comparison between the peptides themselves. Here, only four tendons per group were tested, all at one time point; the investigators did not measure walking or other functions. The paper also leaves the TB-500 product’s peptide sequence unreported. A larger study with later follow-up and functional measurements would be needed to understand how these findings relate to recovery.

Human symptom reports answer narrower questions

The most frequently cited musculoskeletal human report is Lee and Padgett’s 2021 retrospective knee-pain series. Seventeen records were reviewed and sixteen patients were reached by telephone, usually six to twelve months after treatment injected into the knee joint. Eleven of twelve BPC-157-only recipients reported improvement, alongside three of four recipients of BPC-157 plus a preparation described as thymosin beta-4. The small groups were formed by treatment history, with no placebo arm, randomized assignment or standardized test of knee function.

Pain relief is meaningful to a patient, but that survey could not separate a peptide effect from other influences or establish tissue repair. The combination group also cannot establish whether adding a defined TB-500 fragment helps: its reported TB4 identity and uncontrolled four-person design leave both the material comparison and attribution unresolved. The 2026 rat combination result and this human series concern different materials, injuries and endpoints.

FDA’s BPC-157 briefing also discusses older digestive studies, including an ulcerative-colitis conference abstract whose complete trial report was unavailable. Its TB-500 assessment did not identify clinical studies of the evaluated fragment in humans. Human trials of full-length thymosin beta-4 exist, including Sosne, Dunn and Kim’s small eye-drop trial in nine people with severe dry eye, with 28 days of treatment and another 28 days of observation. Changes in eye symptoms and corneal staining after full-length thymosin beta-4 eye drops cannot establish whether injected seven-residue TB-500 improves recovery from a tendon injury.

What the blood and metabolism studies measured

A repair experiment measures the tissue’s response; pharmacokinetics measures what material reaches the body and how it changes over time. He and colleagues (2022) measured intact BPC-157 after intravenous and intramuscular administration in rats and beagle dogs. They separately followed radioactivity derived from labeled peptide. Breakdown products can retain a radioactive label after the original peptide has disappeared, so tissue radioactivity and intact blood peptide describe different analytes.

The TB-500 metabolism experiments similarly distinguish the parent fragment from detected metabolites. A urinary breakdown product is evidence about detection and metabolism; its persistence supplies no numerical human blood half-life. Neither the BPC-157 animal study nor the TB-500 analytical study supplies a matched human exposure comparison. A joint concentration-time graphic would therefore imply measurements the cited research has not established.

What remains uncertain about benefit and safety

Clinical safety remains poorly characterized for both materials. Lee and Burgess (2025) observed two adults who had previously received intravenous BPC-157 through two infusion days and measurements on day three. They reported no adverse symptoms or clinically significant adverse changes in the collected measurements. That small, selected and brief observation provides little information about uncommon events, prolonged exposure or other routes.

The FDA assessments identify additional gaps involving peptide identity, impurities, aggregation and possible immune reactions. For the defined TB-500 fragment, the agency found no human clinical pharmacokinetic, pharmacodynamic or safety study. Sparse safety reporting cannot determine the frequency of harms. Neither compound has an FDA-approved medicinal product.

The direct rat experiment improves the comparison by giving the groups a common injury and assessment. It still leaves major clinical questions open: whether either preparation improves validated function, repair integrity or return to activity in people; whether any effect persists through later remodeling; and how harms compare. Combining the compounds also leaves questions about the exact preparations and how much of each reaches the injured tissue over time. The direct rat study did not establish that the combination made repaired tendons withstand more pulling force than either preparation alone.

Frequently asked questions

Profiles and related reading

References

1. U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23–24, 2026. BPC-157-related bulk drug substances section. 2026.

   Official FDA primary assessment opened on 2026-10-14; July 23–24, 2026 PCAC briefing. Identity tables and human clinical/safety sections; historical ulcerative-colitis conference abstract reported secondhand by FDA.

2. U.S. Food and Drug Administration. FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 Free Base and TB-500 Acetate). Briefing document for the Pharmacy Compounding Advisory Committee, July 23–24, 2026; evaluation dated May 15, 2026.

   Official FDA primary assessment opened on 2026-10-14; evaluation dated May 15, 2026. PDF pages 7–10 identity; pages 23–33 human evidence, pharmacology and safety.

3. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis. 2012;4(9):733–738. DOI: 10.1002/dta.1402. PMID: 22962027.

   Original indexed Wiley graphical abstract and original indexed PubMed abstract read on 2026-10-14. Identification of N-terminal acetylated 17–23 fragment Ac-LKKTETQ in a product labeled TB-500.

4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985). 2011;110(3):774–780. DOI: 10.1152/japplphysiol.00945.2010. PMID: 21030672.

   Original indexed APS full-text passages and original abstract read on 2026-10-14. Abstract and Results: rat tendon explants/fibroblasts; migration, stress survival, FAK/paxillin phosphorylation and unchanged direct proliferation assays.

5. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljar M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2003;21(6):976–983. DOI: 10.1016/S0736-0266(03)00110-4. PMID: 14554208.

   Original indexed Wiley original abstract read on 2026-10-14. Unrepaired rat Achilles transection; intraperitoneal exposure; saline comparator; day 1–14 mechanical, functional and structural assessments.

6. Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024;1235:124033. DOI: 10.1016/j.jchromb.2024.124033. PMID: 38382158.

   Original indexed PubMed abstract and original indexed ScienceDirect abstract/highlights read on 2026-10-14. Methods: Ac-LKKTETQ, human serum/enzyme systems, rat urine and fibroblast assay. Results: Ac-LKKTE activity; parent lacked significant scratch-assay effect.

7. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2003;11(1):19–24. DOI: 10.1046/j.1524-475x.2003.11105.x. PMID: 12581423.

   Original indexed PubMed abstract read on 2026-10-14. Full-thickness skin wounds in diabetic/aged mice; full-length thymosin beta-4 and unacetylated LKKTETQ preparation distinguished.

8. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery. 2026;37(3):822–837. DOI: 10.52312/jdrs.2026.2951. PMID: 42542926.

   Complete original publisher text opened and read on 2026-10-14. Methods endpoint allocation; daily intraperitoneal administration through day 30; Results biomechanical analysis; Figure 2 median/IQR and adjusted pairwise P values. Exact TB-500 sequence not reported.

9. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine. 2021;27(4):8–13. PMID: 34324435.

   Original indexed PubMed abstract read on 2026-10-14. Retrospective chart review; 17 records, 16 phone respondents; intra-articular BPC-157 alone or BPC-157 plus TB4; usual 6–12-month recall.

10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative therapies in health and medicine. 2025;31(5):20–24. PMID: 40131143.

    Original indexed PubMed abstract read on 2026-10-14. Two previously exposed adults; intravenous infusions on two consecutive days; biomarkers/vital signs through day 3.

11. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. DOI: 10.1097/ICO.0000000000000379. PMID: 25826322.

    Original indexed PubMed abstract read on 2026-10-14. Nine people with severe dry eye; full-length thymosin beta-4 eye drops versus vehicle; 28 days treatment and 28 days additional follow-up.

12. He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. DOI: 10.3389/fphar.2022.1026182.

    Original open-access publisher PDF/indexed abstract checked on 2026-10-14; reviewed profile’s previously extracted sampling details retained. No human PK assertion derived. Methods/Results distinguish intact-peptide LC–MS/MS from tritium-derived total radioactivity; intravenous and intramuscular rat/dog pharmacokinetics.